Macugen
·
- Prescription status not stated
- Eyes and ears
- Active substance
- Pegaptanib
- Used in
- Eyes and ears
- Made by
- PharmaSwiss Ceska Republika s.r.o
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
NetherlandsNo exact match for this strength and form
Details
| Made by | PharmaSwiss Ceska Republika s.r.o |
|---|---|
| Active substance | Pegaptanib |
| Used in | Eyes and ears |
| Classification | S01LA03 · Eyes and ears |
| Authorised on | 2006-01-31 |
| Last updated by the regulator | 2022-12-02 |
| EMA product number | EMEA/H/C/000620 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).